Novel Sars-Cov-2 Pandemic Transmission With Ongoing Antiviral Therapies And Vaccine Design
Starting from the end of 2019 the new SARs-CoV-2 virus, in the period of a few months, had spread to 210 countries and its territories. The Wuhan wild animal market, in Hubei province, China is considered the epicenter of this pandemic. WHO declared the name COVID-19 to designate the disease caused by the SARS-CoV-2 virus. It is the third coronavirus pandemic after SARS in 2002–2003 and MERS-CoV in 2012. Genome sequencing of this new COVID-19/SARS-CoV-2 virus shows slight genetic diversity when compared to other coronaviruses. Owing to its pathogenesis, and less known replication cycle, no universal antiviral treatment can be applied and vaccine preparation is still a larger challenge. The present article will highlight transmission, pandemic status, genetic diversity current antiviral therapy, and vaccine trials for COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Postępy Mikrobiologii - 60(2021), 1, Seite 13-20 |
| Sprache: |
Englisch ; Polnisch |
|---|
| Beteiligte Personen: |
Yameen Muhammad [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21307/PM-2021.60.1.02 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ079761607 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ079761607 | ||
| 003 | DE-627 | ||
| 005 | 20230410111005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230308s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21307/PM-2021.60.1.02 |2 doi | |
| 035 | |a (DE-627)DOAJ079761607 | ||
| 035 | |a (DE-599)DOAJd3ff70cfabdc43beb6a34463f82333cb | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a pol | ||
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Yameen Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Sars-Cov-2 Pandemic Transmission With Ongoing Antiviral Therapies And Vaccine Design |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Starting from the end of 2019 the new SARs-CoV-2 virus, in the period of a few months, had spread to 210 countries and its territories. The Wuhan wild animal market, in Hubei province, China is considered the epicenter of this pandemic. WHO declared the name COVID-19 to designate the disease caused by the SARS-CoV-2 virus. It is the third coronavirus pandemic after SARS in 2002–2003 and MERS-CoV in 2012. Genome sequencing of this new COVID-19/SARS-CoV-2 virus shows slight genetic diversity when compared to other coronaviruses. Owing to its pathogenesis, and less known replication cycle, no universal antiviral treatment can be applied and vaccine preparation is still a larger challenge. The present article will highlight transmission, pandemic status, genetic diversity current antiviral therapy, and vaccine trials for COVID-19. | ||
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a who | |
| 650 | 4 | |a viral genome | |
| 650 | 4 | |a covid-19 | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Sattar Sara |e verfasserin |4 aut | |
| 700 | 0 | |a Khalid Ayesha |e verfasserin |4 aut | |
| 700 | 0 | |a Aslam Muhammad Aamir |e verfasserin |4 aut | |
| 700 | 0 | |a Zafar Nishat |e verfasserin |4 aut | |
| 700 | 0 | |a Saeed Muhammad Hassan |e verfasserin |4 aut | |
| 700 | 0 | |a Arif Muhammad Haseeb |e verfasserin |4 aut | |
| 700 | 0 | |a Jahangeer Muhammad |e verfasserin |4 aut | |
| 700 | 0 | |a Qadeer Azka |e verfasserin |4 aut | |
| 700 | 0 | |a Hussain Shoukat |e verfasserin |4 aut | |
| 700 | 0 | |a Aamir Muhammad |e verfasserin |4 aut | |
| 700 | 0 | |a Mukhtar Sania |e verfasserin |4 aut | |
| 700 | 0 | |a Nasir Huma |e verfasserin |4 aut | |
| 700 | 0 | |a Shahzad Asif |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Postępy Mikrobiologii |d Sciendo, 2020 |g 60(2021), 1, Seite 13-20 |w (DE-627)DOAJ000017639 |x 25453149 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:1 |g pages:13-20 |
| 856 | 4 | 0 | |u https://doi.org/10.21307/PM-2021.60.1.02 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/d3ff70cfabdc43beb6a34463f82333cb |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.21307/PM-2021.60.1.02 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2545-3149 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 1 |h 13-20 | ||